Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) Director Nancy Thornberry sold 1,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the completion of the transaction, the director owned 1,109 shares of the company’s stock, valued at $607,576.74. This trade represents a 47.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Trading Down 1.1%
NASDAQ VRTX opened at $514.75 on Friday. The stock’s 50-day simple moving average is $522.72 and its two-hundred day simple moving average is $485.26. Vertex Pharmaceuticals Incorporated has a twelve month low of $412.27 and a twelve month high of $568.67. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $130.51 billion, a price-to-earnings ratio of 31.62, a PEG ratio of 2.85 and a beta of 0.28.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.80 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Vertex Pharmaceuticals during the 2nd quarter valued at about $11,975,849,000. State Street Corp lifted its holdings in Vertex Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 12,024,456 shares of the pharmaceutical company’s stock worth $6,286,506,000 after buying an additional 152,997 shares during the period. Wellington Management Group LLP lifted its holdings in Vertex Pharmaceuticals by 1.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after buying an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Vertex Pharmaceuticals by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after buying an additional 29,287 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $1,509,651,000. 90.96% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
VRTX has been the subject of a number of recent research reports. UBS Group boosted their target price on Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Royal Bank Of Canada lifted their price target on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. Wells Fargo & Company lifted their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Cantor Fitzgerald boosted their price objective on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Finally, The Goldman Sachs Group upped their price objective on shares of Vertex Pharmaceuticals from $654.00 to $725.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $596.44.
View Our Latest Stock Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
